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Improved tolerability and efficaciousness 
of MiraLAX-Gatorade when compared to 
GoLYTELY in the outpatient setting 
BASSEM FARAH, B.S., Wayne State University School of Medicine, gg8930@wayne.edu 
 
ABSTRACT A clinical decision report using Gu P, Lew D, Jung OS, et al. Comparing the Real-World Effectiveness of Competing 
Colonoscopy Preparations: Results of a Prospective Trial. Am J Gastroenterol. 2019;114(2):305-314. 
https://doi.org/10.14309/ajg.0000000000000057 for a patient reluctant to undergo colonoscopy screening due to concerns about 
GoLYTLEY's tolerability. 
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Clinical Context 
Joan Smith (pseudonym) is 52-year-old Caucasian woman that presented to her PCP for an annual check-up. She 
had no complaints, but it was noted that she had not yet had her first colonoscopy. Mrs. Smith had been given 
referrals for the past two years, however, she never went. When asked what her concerns were, Mrs. Smith told us 
that she was embarrassed as she had concerns about the GoLYTELY bowel preparation, as several of her friends 
complained about its tolerability. One of her friends complained of a “disgusting drink that did not go down well” 
and another complained of “knowing what was coming after this drink making it hard to finish.” When asked what 
her biggest barrier with the colonoscopy preparation was, Mrs. Smith mentioned that the thought of having to 
drink something “gross” followed by diarrhea lessened her motivation and is the reason she doesn’t want the 
procedure.  Mrs. Smith agreed that cancer screening was important, as her husband had polyps found when he 
had his procedure done, however, she was curious if she could use MiraLAX-Gatorade, a preparation that her 
husband had tolerated better during that time, instead. 
Clinical Question 
Is the MiraLAX-Gatorade colonoscopy preparation more tolerable and efficacious than GoLYTELY in an outpatient setting? 
Research Article 
Gu P, Lew D, Jung OS, et al. Comparing the Real-World Effectiveness of Competing Colonoscopy Preparations: Results of a 
Prospective Trial. Am J Gastroenterol. 2019;114(2):305-314. https://doi.org/10.14309/ajg.0000000000000057 
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Related Literature 
A search on UpToDate for “bowel preparation” provided a list of the FDA approved colonoscopy preparations. This included 4L 
polyethylene glycol with electrolyte solution (PEG-ELS), which includes GoLYTELY, 2L PEG-ELS, which includes Moviprep, and 
hyperosmotic agents such as Suprep. MiraLAX is a non-FDA approved OTC bowel preparation that works similarly to GoLYTELY. It is 
often mixed with 2L of Gatorade and used as bowel preparation. A PubMed search of “colonoscopy bowel preparation AND 
Gatorade” and colonoscopy bowel preparation AND MiraLAX provided several articles on this topic. There is conflicting literature on 
the bowel cleansing effectiveness of MiraLAX-Gatorade when compared to GoLYTELY. The Enestvedt and the Hjelkrem studies were 
among the first randomized controlled trials (RCTs) to study to efficacy of MiraLAX-Gatorade. They both concluded that it was 
inferior to GoLYTELY in bowel preparation quality, determined by the Boston Bowel Preparation Scale (BBPS) scores and Ottawa 
scores respectively.1,2 Another Enestvedt study later determined that MiraLAX-Gatorade also produced lower adenoma detection 
rates than GoLYTELY.3 This led to the conclusion that GoLYTELY should be used as first line for bowel preparation.  
There were 2 RCTs that concluded MiraLAX-Gatorade was a non-inferior preparation when compared to GoLYTELY. The different 
result in the McKenna study was attributed to the lack of split dosing, which was used prior. The McKenna study also had 
independent researchers assign the BBPS score based off pictures of bowel, as opposed to by the endoscopists.4 The Samarasena 
study utilized the Ottawa score and the BBPS score, which was assigned by independent researchers observing a video of the 
procedure. In addition, MiraLAX-Gatorade consistently scored higher on patient tolerability surveys in this study, which asks about 
specific symptoms such as nausea, bloating, cramping, discomfort, and sleep disturbance.5 This was the first study where bowel 
preparation tolerability was assessed. Another article was a retrospective endoscopic database analysis at a community hospital, 
which concluded that MiraLAX-Gatorade-bisacodyl provided a statistically significant improvement to bowel cleansing.6 This was 
attributed to improved compliance when compared to GoLYTLEY. The Govani study, which was a retrospective analysis, tested the 
impact of many different variables on bowel preparation efficacy. It found that MiraLAX-Gatorade preparations were associated 
with better bowel preparation, assessed by endoscopists.7 The first meta-analysis on MiraLAX-Gatorade effectiveness found that it 
was inferior to GoLYTLEY.8 This analysis included 1418 patients and utilized 5 different studies, including the Enestvedt and Hjelkrem 
studies. A later meta-analysis by Zhang utilized regression with random effects on the same data and found that no significant 
difference existed between the groups, leading to the conclusion that many variables impact preparation efficacy.9  
Many of the previously listed studies tested the effectiveness of MiraLAX-Gatorade in a controlled setting with monitored protocols; 
however, the clinical effectiveness of MiraLAX-Gatorade in a “real-world” setting has not been extensively studied. Gu et al. 
provided a prospective, naturalistic comparative effectiveness study to assess the effectiveness and tolerability of different 
colonoscopy preparations.10 This makes it more applicable to the outpatient setting, as patient tolerability can determine 
preparation effectiveness and was Mrs. Smith’s primary concern. The level of evidence of this study is 2 using the SORT algorithm, as 
it is an observational study. Despite this, a study that mimicked outpatient colonoscopies and measured both efficacy and 
tolerability was required to answer the clinical question, making this paper ideal. 
Critical Appraisal 
This study was conducted at Cedars-Sinai Hospital in Los Angeles, California. To be eligible, patients had to have an outpatient 
colonoscopy from August 4th, 2016 to July 31st, 2018 and be ≥ 18. Age, BMI, race/ethnicity, sex, language, opioid/tricyclic 
antidepressant use, and comorbidities of patients were noted. Patients were primarily Non-Hispanic white (2952) and 51% female, 
with the majority aged 50-64 (1763). Bowel cleansing was assessed using the routine BBPS score, which is assigned by a nurse during 
the colonoscopy. Adequate bowel cleansing was defined as a total BBPS score of ≥ 6. Bowel preparation tolerability was assessed 
through a question asked to each patient. Prior to the procedure, the nurse asked each patient “How much of the bowel prep did 
you ingest,” with answer options being all (100%), 75-99%, <75%, or unsure. This was further categorized into “fully completed” and 
“not fully completed” groups. Endoscopists were free to give any preparation and dose, and patients were asked which preparation 
they used prior to the procedure. GoLYTELY, Colyte, NuLYTELY, Trilyte, MoviPrep, MiraLAX-Gatorade, Suprep, Suclear, Prepopik, 
OsmoPrep, and magnesium citrate were all used; however, Colyte, NuLYTELY, and Trilyte were grouped with GoLYTELY due to similar 
formulation. 
Overall, 5253 outpatient colonoscopies were completed, with 914 cases excluded either due to age < 18 (257), using two day 
preparations or unknown dosing (184), absent colons or procedure termination other than suboptimal preparation (93), or missing 
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scoring data (383). The study included 4339 colonoscopies, performed by 75 different independent providers. The results showed 
that MiraLAX-Gatorade had a 92.6% completion rate, whereas GoLYTELY had an 82.9% completion rate. Upon adjusting for 
preparation, provider, and patient-related variables using multivariable logistic regression analysis with random effects, patients 
using MiraLAX were significantly more likely to finish the preparation, with a rate of 62.3% compared to 11.8% for GoLYTELY (p < 
0.001). MiraLAX-Gatorade also had the highest adjusted completion rate when compared to the other preparations. With regards to 
the bowel cleansing efficacy, MiraLAX-Gatorade had an average BBPS score of 7.09±1.64 whereas GoLYTELY had an average score of 
6.67±1.87 after multivariable regression analysis, which was significant (p < 0.001). Patients using MiraLAX-Gatorade also had higher 
odds for adequate cleansing when compared to GoLYTELY (OR, 1.76; 95% CI, 1.24-2.49). MoviPrep and Suprep also had higher 
completion rates and BBPS scores than GoLYTELY. Patients told to use split-prep dosing also had higher total BBPS scores.  
Several characteristics contributed to the strength of this study. This was the largest prospective study analyzing both the tolerability 
and efficacy of various bowel preparations, with over 4300 colonoscopies included. In addition, because there were over 75 
providers that could prescribe any regimen, this study can compare many different bowel preparations. Patients were also not 
excluded for having chronic conditions such as chronic opioid use, inflammatory bowel disease, chronic kidney disease, congestive 
heart failure, and cirrhosis.10 This is in contrast to the RCTs previously listed, which typically include fewer, more controlled regimens 
and excluded patients with chronic conditions.1,4,5 This study was also free of the Hawthorne effect and remuneration, as it was not 
a RCT. Multiple RCTs have found GoLYTELY to have superior efficacy when compared to MiraLAX-Gatorade1,2,3; however, patients 
may be more willing to fully ingest GoLYTELY, despite its lower tolerability, due to these biases. This makes prospective, naturalistic 
trials like the Ru study more closely reflect outpatient clinical care. Regression analysis with random effects also improves the 
strength of these results, as it controlled for unobserved heterogeneity.  
The authors chose to exclude patients less than 18 years old, those with surgically absent colons, those that were unable to 
complete the BBPS due to reasons other than bowel prep, and those with missing data. These patients were eliminated because 
they could not be scored using the BBPS, which was used as the primary measure for the manuscript. While this could have had an 
impact on the final outcome, the overall sample size was large enough that the conclusions can still be seen as a generalized 
outcome for a broader population. In addition, MiraLAX-Gatorade was found to have superior BBPS scores and tolerability, the 
impact of this is not clear because the minimum score before which the adenoma detection rate decreases and interval colorectal 
carcinoma development increases has not been determined. Because this study was conducted at a single site, there were also 
concerns about generalizability. This was somewhat offset by the large sample size and diverse patient cohorts. With regards to the 
assessment of bowel cleansing efficacy, since BBPS scores are assigned by the nurse who participated in the procedure, variability in 
scoring exists. This was addressed through the in-service training that was given to the nurses participating. The lack blinded 
reviewers of the BPPS scores could also be a flaw, but this made the study better reflect clinical practice and eliminate observer bias. 
Providers selecting regimens may have been biased but having 75 participating helps lessen this. Regression analysis with random 
effects accounted for differences in the providers such as endoscopic skills and experience, personal bowel cleansing thresholds, and 
patient population. Finally, the study was unable to account for patients who missed or canceled their procedure. Patients with 
intolerable preparations may have been part of this group, meaning tolerability and bowel cleansing effects of GoLYTELY may have 
been overestimated. There were no significant conflicts of interest, although the authors received a consulting fee from Bayer, 
which makes Miralax. This should not affect the results as providers chose the regimens. 
Clinical Application 
The authors concluded that MiraLAX-Gatorade, MoviPrep, and Suprep have superior tolerability and are associated 
with better bowel cleansing in patients aged ≥ 18 when compared to GoLYTELY. They also noted that split dosing 
was associated with superior cleansing. Because this study used outpatient data and Mrs. Smith fit the majority 
demographic of a Caucasian female aged 50-64 with BMI < 25 without any comorbidities, split dose MiraLAX-
Gatorade was recommended. In addition, Mrs. Smith had the greatest likelihood of tolerating the MiraLAX-
Gatorade, which was her biggest concern. We explained to her that while GoLYTELY was found to be superior in a 
controlled setting, when you consider people’s real-world concerns and limitations with finishing the bowel 
preparation, MiraLAX-Gatorade had better bowel cleansing outcomes due to its better tolerability. Each of the 
factors mentioned could have changed the clinical decision making, but for Mrs. Smith, they solidified the choice 
that we made. We are confident in our decision to have Mrs. Smith have a split dose of MiraLAX-Gatorade, even 
though it was not found to be the most effective treatment in other manuscripts because in this clinical context it 
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fit her needs the best. Mrs. Smith had been nervous and embarrassed about not having had the colonoscopy done 
sooner and was thankful that we listened to her concerns and found something that would work for her. 
New Knowledge Related To Clinical Decision Science 
Screening for malignancy only works if the patient is actually screened. This report highlights a common clinical problem. In the 
clinical setting, convincing a patient who would otherwise decline screening depends on understanding and accepting the patient’s 
perspective. Clinical Decision Science asks multiple questions related to this patient. How many patients are never screened because 
of concerns related to the bowel prep? What other types of screening are available and acceptable to the patient? In this case, the 
patient herself suggests a solution to her personal barrier for screening.  
This report is a good example of using evidence that best fits a patient’s concerns. Had we only used the older RCTs in deciding what 
to recommend to Mrs. Smith, we would have recommended GoLYTELY due to superior bowel preparation and adenoma detection 
rates.1,2 While this would work in inpatient settings where you can monitor if a patient finishes the bowel preparation, in outpatient 
settings this is unrealistic. Newer studies have since included tolerability and have shown that better tolerability plays a major role in 
showing that Miralax-Gatorade has either non-inferior or even superior cleansing. The Gu study is relevant to Mrs. Smith as she had 
concerns about the preparation’s taste and adding Gatorade would help with that. Including tolerability, the large sample size that 
fits Mrs. Smith’s demographic, and use of outpatient data are the main reasons this article is superior to other articles and  is the 
reason that recommending Miralax-Gatorade was the best decision for her. Because of the contradictory data, it is important to look 
at the patient demographics of each article and who the findings best apply to before applying their conclusions to your patients, as 
each patient’s backgrounds and concerns are unique. 
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